Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05898503
Other study ID # EODTOEOCFIPHW
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date April 23, 2023
Est. completion date December 31, 2024

Study information

Verified date April 2023
Source Beijing Sport University
Contact Peizhen Zhang
Phone 01062989581
Email zhpzh@bsu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Brief Summary: The study was conducted in two parts, the first of which was carried out using a cross-sectional design approach to explore the relationship between cognitive function and autonomic function, brain function, inflammation and oxidative stress, vascular function, fitness levels, cardiorespiratory endurance and lipid metabolism. The second part uses a repeated measures design approach in a randomised controlled design to explore the effects of different types of exercise on cognitive decline in postmenopausal hypertensive women and their mechanisms of action.


Description:

Detailed Description: The study was conducted in 2 parts. Part I: was conducted using a cross-sectional design approach to explore the relationship between cognitive function and autonomic function, brain function, inflammation and oxidative stress, vascular function, fitness levels, cardiorespiratory endurance and lipid metabolism. Multiple linear regression was used to analyse the multiple linear relationships between changes in cognitive function and the above influences. Multiple logistic regression analysis was also used to analyse which of the above risk factors might be independent predictors of cognitive decline. Therefore, a combination of both regression analyses was used to further explore the multiple linear relationships between cognitive function and the aforementioned influencing factors, providing a viable causal and theoretical basis for the next exercise intervention. The second part of the study is to test the viability of the vascular function theory. The "vascular function theory" refers to the use of exercise to improve aerobic capacity, improve blood circulation to the heart, and improve cerebrovascular function, which in turn improves cognitive function. Based on the above hypothesis, this study aims to investigate the possible effects of 12 weeks of different types of exercise on cognitive decline in post-menopausal women with HTN, and to lay the theoretical and practical foundation for the extension of the exercise intervention to other ages and populations.


Recruitment information / eligibility

Status Recruiting
Enrollment 183
Est. completion date December 31, 2024
Est. primary completion date April 23, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 55 Years to 65 Years
Eligibility 1. postmenopausal HTN women aged 55 to 65 years 2. 140 mm Hg = SBP < 160 mm Hg) and/or 90 mmHg < DBP < 99 mmHg (2016 edition of the Chinese guidelines for hypertension control) 3. non-persistent hypertension (i.e., continuous use of three or more antihypertensive drugs and blood pressure still within the normal range, or continuous use of four or more antihypertensive drugs to control blood pressure 4. no other metabolic and cardiovascular problems 5. able to participate in physical activity 6. no exercise habit (no more than 6,000 steps per day) 7. alcohol and smoking prohibited 8. moderate risk classification of having cardiovascular disease 9. voluntary participation Exclusion criteria: 1 pre-menopausal, not falling under the above conditions 2 blood pressure not exceeding the above range 3 refractory hypertension and secondary hypertension 4 metabolic and cardiovascular diseases 5 unable to exercise for their own reasons 6 regular exercise (more than 6,000 steps per day) 7 poor lifestyle habits such as alcohol and smoking 8 suffering from cardiovascular disease risk classification of high or low b. Inclusion criteria for the negative control group: 1. postmenopausal women aged 55 to 65 years 2. SBP = 120 mmHg, DBP < 90 mmHg 3. good physical condition 4. practice daily exercise (more than 6000 times daily) 5. do not drink or smoke 6. have a risk classification of no risk for cardiovascular disease 7. voluntary participation Exclusion criteria: 1. pre-menopausal and not in the above category 2. SBP and DBP values below normal 3. general health, disability or other medical conditions 4. poor diet, alcohol abuse, smoking, etc. 5. no low risk cardiovascular risk classification

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Walking exercise + resistance training
Walking exercise and resistance training for 12 weeks
Resistance training
Resistance training for 12 weeks
Walking exercise
Walking exercise for 12 weeks
Health promotion
Health promotion for 12 weeks

Locations

Country Name City State
China School of Sports Medicine and Rehabilitation, Beijing Sport University Beijing

Sponsors (1)

Lead Sponsor Collaborator
Beijing Sport University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary MOCA score The change of MOCA score. Montreal cognitive assessment (MoCA). The MoCA scale includes cognitive functions such as visuospatial and executive functions, naming, attention, language, abstraction, delayed recall and orientation, and evaluates the level of cognitive function from several cognitive dimensions. The MoCA has a total score of 30 questions, with 26 being normal and <26 being cognitive decline. 12 weeks
Secondary Blood pressure The change of blood pressure before and after intervention. 12 weeks
Secondary Quiet heart rate The change of quiet heart rate before and after intervention. 12 weeks
Secondary Waist and hip circumference The change of waist circumference and hip circumference before and after intervention. 12 weeks
Secondary Body fat percentage The change of body fat percentage before and after intervention. 12 weeks
Secondary Lipid metabolism indicators The change of lipid metabolism indicators before and after intervention. Lipid metabolism indicators include: total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C). 12 weeks
Secondary Cardiorespiratory endurance indicator The change of cardiopulmonary endurance indicator before and after intervention. Cardiopulmonary endurance indicator: maximal oxygen uptake (VO2max) was determined using exercise cardiorespiratory testing system. 12 weeks
Secondary Serum interleukin-6 (IL-6) The change of inflammation indicators before and after intervention. 12 weeks
Secondary High-sensitivity C-reactive protein (hs-CRP) The change of inflammation indicators before and after intervention. 12 weeks
Secondary Vascular endothelial growth factor (VEGF) The change of growth factor indicators before and after intervention. 12 weeks
Secondary Insulin-like growth factor(IGF-1) The change of growth factor indicators before and after intervention. 12 weeks
Secondary Malondialdehyde (MDA) The change of malondialdehyde (MDA) level before and after intervention. 12 weeks
Secondary Superoxide dismutase (SOD) The change of superoxide dismutase (SOD) level before and after intervention. 12 weeks
Secondary Nitric oxide (NO) The change of nitric oxide (NO) level before and after intervention. 12 weeks
Secondary Heart rate variability (HRV) The change of heart rate variability (HRV) before and after intervention. 12 weeks
Secondary Mean flow rate (Vm) of middle cerebral artery and carotid artery The change of middle cerebral artery mean flow rate and carotid artery mean flow rate before and after intervention. 12 weeks
Secondary Resistance index (RI) of middle cerebral artery and carotid artery The change of middle cerebral artery resistance index and carotid artery resistance index before and after intervention. 12 weeks
Secondary Pulsatility index (PI) of middle cerebral artery and carotid artery The change of middle cerebral artery pulsatility index and carotid artery pulsatility index before and after intervention. 12 weeks
Secondary Peak systolic velocity (PSV) and end-diastolic velocity (EDV) of carotid artery The change of peak systolic velocity and end-diastolic velocity of carotid artery before and after intervention. 12 weeks
Secondary Vascular endothelial function indicator: Flow-mediated dilation (FMD) The change of flow-mediated dilation before and after intervention. 12 weeks
Secondary Artery stiffness indicator: Carotid-femoral pulse artery stiffness (cfPWV). The change of carotid-femoral pulse artery stiffness (cfPWV) before and after intervention. 12 weeks
See also
  Status Clinical Trial Phase
Terminated NCT04591808 - Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia Phase 3
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT05433233 - Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension N/A
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Completed NCT03093532 - A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT05529147 - The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Recruiting NCT05976230 - Special Drug Use Surveillance of Entresto Tablets (Hypertension)
Completed NCT06008015 - A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers Phase 1
Completed NCT05387174 - Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period N/A
Completed NCT04082585 - Total Health Improvement Program Research Project
Recruiting NCT05121337 - Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension N/A
Withdrawn NCT04922424 - Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men Phase 1
Active, not recruiting NCT05062161 - Sleep Duration and Blood Pressure During Sleep N/A
Completed NCT05087290 - LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
Not yet recruiting NCT05038774 - Educational Intervention for Hypertension Management N/A
Completed NCT05621694 - Exploring Oxytocin Response to Meditative Movement N/A
Completed NCT05688917 - Green Coffee Effect on Metabolic Syndrome N/A
Recruiting NCT05575453 - OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure N/A